| Accession |
PRJCA023471 |
| Title |
A RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY |
| Relevance |
Medical |
| Data types |
Nucleotide data:MRD ctDNA - Negative
|
| Organisms |
Homo sapiens
|
| Description |
This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in patients with MIBC who are ctDNA positive and are at high risk for recurrence following cystectomy. The purpose of this study is to assess the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in patients with muscle-invasive bladder cancer (MIBC) who are circulating tumor DNA (ctDNA) positive and are at high risk for recurrence following cystectomy.Because of the high risk of relapse with surgery alone, neoadjuvant and adjuvant treatments have been utilized in conjunction with radical cystectomy for MIBC. However, there is an urgent need for effective regimens for patients who decline or are ineligible for neoadjuvant chemotherapy or adjuvant chemotherapy. |
| Sample scope |
Multiisolate |
| Release date |
2024-04-09 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Roche/Genentech
|
|
NA
|
|
|
|
| Submitter |
Dingwei
Ye (fuscc2012@163.com)
|
| Organization |
Fudan University Shanghai Cancer Center |
| Submission date |
2024-02-05 |
